Looking at this filing, I can see it's a Form 10-Q for Context Therapeutics Inc. for the quarterly period ended September 30, 2026. The filing content provided is primarily the cover page, table of contents, and forward-looking statements section. The substantive financial disclosure content (financial statements, MD&A figures, specific financial results) is referenced in the table of contents but the actual text was cut off. However, the cover page and forward-looking statements section do contain substantive disclosure content including product pipeline information, company status (smaller reporting company, emerging growth company), share count, and program details exceeding 150 words.

Context Therapeutics Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Share count: As of November 6, 2026, Context Therapeutics reported 91,879,177 shares of common stock outstanding.
  • Exchange listing: The company's common stock (par value $0.001 per share) is listed on NASDAQ:CNTX.
  • Company classification: The registrant is identified as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Active pipeline: The filing identifies CTIM-76 and CT-202 as the company's prioritized product candidates, with CT-95 in wind-down.
  • Going concern disclosure: The company disclosed plans to seek additional capital through equity and/or debt financings, partnerships, collaborations, licensing agreements, or other strategic arrangements.
  • Nasdaq compliance: The filing references plans "to regain and maintain compliance with the continued listing requirements of The Nasdaq Stock Market" as a forward-looking matter subject to uncertainty.

Context Therapeutics Pipeline Status and Filing Details for the September 2026 Quarter

Context Therapeutics Inc., a Delaware-incorporated biopharmaceutical company headquartered at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103, filed its quarterly report covering the period ended September 30, 2026. The company's common stock trades under the symbol CNTX on The Nasdaq Stock Market LLC with a par value of $0.001 per share. As of November 6, 2026, the company reported 91,879,177 shares of common stock outstanding, according to the filing.

According to the filing, the company's development focus is on two prioritized product candidates: CTIM-76 and CT-202. The filing also references "the wind down of the CT-95 Phase 1 clinical trial," describing CT-95 as a discontinued internal development program. The company disclosed forward-looking considerations regarding "the timing, progress and results of preclinical studies and clinical trials for CTIM-76, CT-202 and other product candidates," as well as the "timing, scope and likelihood of U.S. and foreign regulatory filings and approvals, including timing of Investigational New Drug (IND) applications." These statements are the company's own and are subject to its cautionary language regarding known and unknown risks and uncertainties.

The company disclosed that it currently has no revenue-generating approved products and that it expects to require additional financing. The filing states the company's current plans include seeking "additional capital in the future through equity and/or debt financings, partnerships, collaborations, licensing agreements or other strategic arrangements, or other sources." Additionally, the company acknowledged uncertainty about "our ability to continue as a going concern, including the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements," according to the filing. The filing confirmed the company has met all required SEC report submission obligations during the preceding 12 months and has submitted all required Interactive Data Files electronically.

What Was Disclosed

Context Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 91,879,177 shares outstanding as of November 6, 2026, its NASDAQ:CNTX listing, its pipeline focused on CTIM-76 and CT-202, and the wind-down of the CT-95 program.